The Centers for Disease Control and Prevention (CDC) with the help of the American Pharmacists Association (APhA) Foundation has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists, which is intended to improve healthcare quality.
The Centers for Disease Control and Prevention (CDC) with the help of the American Pharmacists Association (APhA) Foundation has developed a tool kit for instituting collaborative practice agreements between healthcare providers and pharmacists, which is intended to improve healthcare quality.
The target audience for this resource material is pharmacists, other healthcare providers, payers, and decision-makers of collaborative practice agreements. Under state law, a pharmacist collaborative practice agreement is “a formal agreement in which a licensed provider makes a diagnosis, supervises patient care, and refers patients to a pharmacist under a protocol that allows the pharmacist to perform specific patient care functions,” according to CDC.
“Research shows us that a patient’s control of their blood pressure improves when their care is provided by a team of health professionals,” said David Callahan, MD, with CDC. “This tool kit will play an invaluable role in allowing physicians and pharmacists to work together to give patients optimal are and save lives by controlling blood pressure.”
The content for the tool kit was developed with input from APhA Foundation following a consortium on collaborative practice agreements and pharmacists’ patient care services held in January 2012. Case studies from Osterhous Pharmacy in eastern Iowa, Goodrich Pharmacy in Minnesota, and El Rio Community Health Center in Arizona were good examples of pharmacist patient care services performed under collaborative practice agreements.
The document also outlined action steps for pharmacists to help build and strengthen these collaborative agreements:
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More